Literature DB >> 20085690

Severe hospitalised 2009 pandemic influenza A(H1N1) cases in France, 1 July-15 November 2009.

C Fuhrman1, I Bonmarin, A C Paty, N Duport, E Chiron, E Lucas, D Bitar, A Mailles, M Herida, S Vaux, D Lévy-Bruhl.   

Abstract

From 1 July 2009 to 15 November 2009, 244 patients with 2009 pandemic influenza A(H1N1) were admitted to intensive care unit (ICU) and were compared with 514 cases hospitalised in medical wards in France until 2 November 2009. Detailed case-based epidemiological information and outcomes were gathered for all hospitalised cases. Infants and pregnant women are overrepresented among cases admitted to ICU with seven per cent for both groups respectively, and twenty per cent of ICU cases did not belong to a risk group. Chronic respiratory disease was the most common risk factor among cases but obesity (body mass index >or= 30 Kg/m(2)), chronic cardiac disease and immunosuppression were risk factors associated with severe illness after adjustment for age and for other co-morbidities.

Entities:  

Mesh:

Year:  2010        PMID: 20085690     DOI: 10.2807/ese.15.02.19463-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  35 in total

1.  Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.

Authors:  Manjunath P Pai; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 2.  Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature.

Authors:  Anandi N Sheth; Keri N Althoff; John T Brooks
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

3.  The 2009 pandemic H1N1 and triple-reassortant swine H1N1 influenza viruses replicate efficiently but elicit an attenuated inflammatory response in polarized human bronchial epithelial cells.

Authors:  Hui Zeng; Claudia Pappas; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

4.  Incidence of hospital admissions and severe outcomes during the first and second waves of pandemic (H1N1) 2009.

Authors:  Melissa Helferty; Julie Vachon; Jill Tarasuk; Rachel Rodin; John Spika; Louise Pelletier
Journal:  CMAJ       Date:  2010-11-08       Impact factor: 8.262

Review 5.  Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic.

Authors:  Anandi N Sheth; Pragna Patel; Philip J Peters
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

6.  Surveillance of hospitalizations with pandemic A(H1N1) 2009 influenza infection in Queensland, Australia.

Authors:  Hai Phung; Frank Beard; Christine Selvey; Ranil Appuhamy; Frances Birrell
Journal:  Western Pac Surveill Response J       Date:  2011-05-30

Review 7.  Obesity and respiratory infections: does excess adiposity weigh down host defense?

Authors:  Peter Mancuso
Journal:  Pulm Pharmacol Ther       Date:  2012-05-24       Impact factor: 3.410

Review 8.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

9.  Low clinical burden of 2009 pandemic influenza A (H1N1) infection during pregnancy on the island of La Réunion.

Authors:  Patrick Gérardin; Rachid El Amrani; Béatrice Cyrille; Marc Gabrièle; Philippe Guillermin; Malik Boukerrou; Brahim Boumahni; Hanitra Randrianaivo; Arnaud Winer; Jean-Fabien Rouanet; Michel Bohrer; Marie-Christine Jaffar-Bandjee; Pierre-Yves Robillard; Georges Barau; Alain Michault
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

10.  Pulmonary surfactant lipids inhibit infections with the pandemic H1N1 influenza virus in several animal models.

Authors:  Mari Numata; James R Mitchell; Jennifer L Tipper; Jeffrey D Brand; John E Trombley; Yoji Nagashima; Pitchaimani Kandasamy; Hong Wei Chu; Kevin S Harrod; Dennis R Voelker
Journal:  J Biol Chem       Date:  2019-12-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.